Announcement

Collapse
No announcement yet.

Cell: Structural Basis of Zika Virus-Specific Antibody Protection

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Cell: Structural Basis of Zika Virus-Specific Antibody Protection

    Structural Basis of Zika Virus-Specific Antibody Protection

    Haiyan Zhao7
    , Estefania Fernandez7
    , Kimberly A. Dowd
    , Scott D. Speer
    , Derek J. Platt
    , Matthew J. Gorman
    , Jennifer Govero
    , Christopher A. Nelson
    , Theodore C. Pierson
    , Michael S. DiamondPress enter key for correspondence informationPress enter key to Email the author
    , Daved H. FremontPress enter key for correspondence informationPress enter key to Email the author
    7Co-first author

    Publication stage: In Press Corrected Proof

    DOI: http://dx.doi.org/10.1016/j.cell.2016.07.020

    Article Info

    Highlights

    • ?New ZIKV-specific monoclonal antibodies are identified
    • ?Three distinct epitopes on E protein DIII are defined by X-ray crystallography
    • ?DIII lateral ridge antibodies broadly neutralize ZIKV infection and protect in mice



    Summary

    Zika virus (ZIKV) infection during pregnancy has emerged as a global public health problem because of its ability to cause severe congenital disease. Here, we developed six mouse monoclonal antibodies (mAbs) against ZIKV including four (ZV-48, ZV-54, ZV-64, and ZV-67) that were ZIKV specific and neutralized infection of African, Asian, and American strains to varying degrees. X-ray crystallographic and competition binding analyses of Fab fragments and scFvs defined three spatially distinct epitopes in DIII of the envelope protein corresponding to the lateral ridge (ZV-54 and ZV-67), C-C? loop (ZV-48 and ZV-64), and ABDE sheet (ZV-2) regions. In vivo passive transfer studies revealed protective activity of DIII-lateral ridge specific neutralizing mAbs in a mouse model of ZIKV infection. Our results suggest that DIII is targeted by multiple type-specific antibodies with distinct neutralizing activity, which provides a path for developing prophylactic antibodies for use in pregnancy or designing epitope-specific vaccines against ZIKV.

    full article



Working...
X